Latest Strategic Pivot News

Wellnex Life has agreed to sell its Pain Away brand to Mentholatum Australasia for up to A$21.3 million, aiming to wipe out debt and sharpen its strategic focus.

Harris Technology’s refurbished tech division surpassed $1 million in monthly sales for the first time in July 2026, nearly doubling year-on-year revenue and becoming the company’s main earnings driver.

Challenger Gold has completed an A$85 million equity raise backed by key insiders and appointed a new leadership team to drive its transition from exploration to development at Hualilan and El Guayabo.

Godolphin Resources intensifies exploration at Mt Aubrey and Copper Hill East, leveraging a streamlined portfolio and a strategic pivot to precious and base metals in NSW’s Lachlan Fold Belt.

Spacetalk Ltd has locked in $10 million through a two-tranche share placement, aiming to fund platform enhancements, inventory growth, and a major network migration.

Galilee Energy has agreed to sell its Glenaras Gas Project subsidiary to Novus Energy, freeing up capital and management focus to accelerate its US Gulf Coast oil and gas ambitions while retaining a royalty interest in Glenaras.

Vertex Minerals has initiated mechanised longhole stoping at its Reward Gold Mine, targeting narrow, high-grade veins to boost productivity and reduce dilution, with early results showing promising gold grades.

Ava Risk Group has appointed Bryant Henson as CEO to spearhead its next growth phase, with a sharp focus on expanding its footprint in the United States and strengthening commercial execution worldwide.

HSBC Bank Australia is exiting its retail loan business by selling a AUD36 billion home and personal loan portfolio to Blackstone-managed funds, with completion targeted for early 2027 pending regulatory approval.

HSBC Bank Australia has struck a deal to offload its AUD36 billion home and personal loan book to Blackstone-managed funds, marking a strategic retreat from retail lending and a reshaping of its Australian operations.

Acrux Limited’s FY26 receipts soared 960% to $5 million, fuelled by licensing milestones and growing generic sales, while FDA guidance clears the way for pivotal Phase III trials of its Female Testosterone therapy.

1414 Degrees secured $8.45 million funding and inked major agreements to commercialise its SiNTL battery technology across AI data centres, drones, satellites and defence sectors.